BioIQ and Assurance Scientific Laboratories have entered a partnership to bring over-the-counter (OTC) RT-PCR Covid-19 testing to market.
The direct-to-consumer format of the test received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA). It helps to test asymptomatic individuals for Covid-19 without requiring a prescription from the physician.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The solution expands BioIQ’s broad digital health platform for Covid-19 testing and vaccination, which covers home, worksite, community, and retail settings.
The Assurance Scientific offering enhances BioIQ’s retail pharmacy solutions and also expands access to and the convenience of Covid-19 testing to support counteract social determinant of health (SDOH) variables and healthcare discrepancies caused by Covid-19.
BioIQ noted that the OTC at-home test kit can be collected at a retail or employer site.
Using a nasal swab, the sample is collected in an at-home setting and can be sent for sample processing in a prepaid mailer to Assurance Scientific within 24-48 hours.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe results can be accessed on BioIQ’s testing portal that supports population analytics and contact tracing. It also extends integrated telehealth services for providing assistance with the collection of sample and results consultation.
BioIQ founder, president, and COO Justin Bellante said: “The BioIQ platform supports the consumerisation of healthcare with home-based testing for Covid-19 and a variety of other serious health conditions.
“This OTC Covid-19 test and partnership opens BioIQ retail pharmacy solutions for point-of-care testing and vaccination and adds an element of convenience to employer and community testing programmes.”
The OTC test addition to the digital diagnostic testing network of BioIQ comes soon after the launch of Covid-19 variant testing and mobile, on-site Covid-19 worksite testing solutions available through the national lab network of BioIQ.
Last June, BioIQ partnered with P23 Labs to launch a new at-home test for Covid-19 that combines Covid-19, Flu A / Flu B, and a 21 Test Respiratory Panel from a single saliva sample.
